



Contact: Jim Hamby
Ash Stevens Inc.
jhamby@ashstevens.com
734-282-3370 x 1144

Ken Li
Chempetitive Group
kli@chempetitive.com
312-997-2436 x 112

**Ash Stevens Inc. to Present Development of Highly Potent Anti-Cancer Drug Busulfan at
AACR Annual Meeting
*ASI CEO to Chair Session on Cancer Drug Development***

Detroit, Mich.—April 8, 2010—Vince Ammoscato, Vice President of Operations at Ash Stevens Inc. (ASI), will present on the development and manufacture of the highly potent myeloablative agent busulfan used to treat chronic myelogenous leukemia (CML). The presentation will take place at the American Association for Cancer Research (AACR) annual meeting Saturday, April 17 in Washington, D.C. Mr. Ammoscato will present on the handling and manufacture of the highly potent busulfan active pharmaceutical ingredient (API) as well as provide an overview of the challenges and considerations central to developing and manufacturing highly potent cytotoxic agents.

Mr. Ammoscato's presentation is part of the Chemistry in Cancer Research Working Group (CICR) educational session. Chaired by ASI President and CEO Stephen Munk, PhD, the session will highlight the challenges of developing and manufacturing highly potent APIs used in anti-cancer drugs. In addition to Ash Stevens, ARIAD Pharmaceuticals, Infinity Pharmaceuticals, and The National Institutes of Health (NIH) will present methods of addressing challenges in discovering and developing anti-cancer drugs. A schedule for the session is included below.

Educational Session Details

Session Title: From Chemistry to the Clinic, Part 3: Chemical Development – Translating a Potent Agent into a Registered Product

Date: Saturday, April 17

Time: 1:00 p.m. to 3:00 p.m. EST

Location: Room 147, Walter E. Washington Convention Center

Chairperson: Stephen A. Munk, President and CEO of Ash Stevens Inc.

Presentations:

1:00 PM *On the road from research to reality: Pharmaceutical product development concepts for potent compounds, including AP24534, a novel multi-targeted kinase inhibitor*

Christopher K. Murray, ARIAD Pharmaceuticals, Inc., Cambridge, MA

1:30 PM *Discovery and development of the indenoisoquinolines topoisomerase I inhibitors*

Yves G. Pommier, National Institutes of Health, Bethesda, MD

2:00 PM *Pharmaceutical development challenges of the Hsp90 inhibitor IPI-504: A case study in controlling impurity*

Kristopher M. Depew, Infinity Pharmaceuticals, Inc., Cambridge, MA

2:30 PM *The role of the chemical development team in the regulatory approval of a cancer drug*

Vince Ammoscato, Vice President of Operations, Ash Stevens Inc.,
Detroit, MI

About Ash Stevens, Inc.

Ash Stevens, Inc. (ASI) is a Contract Pharmaceutical Manufacturer founded in 1962. Headquartered in Detroit Michigan, ASI has extensive experience with the development and scale-up of commercial cancer APIs (Active Pharmaceutical Ingredients) and shares a longstanding and successful relationship with the National Cancer Institute. To date, ASI has 10 FDA approvals for drug substances that include manufacturing approvals for the active ingredients in Velcade[®], Vidaza[®], and Clolar[®]. The company has an excellent global regulatory compliance history and has been inspected by Ministries of Health from Japan, Korea, Mexico, Australia, European Union and the United States. Ash Stevens is a preferred contractor for the development and cGMP manufacture of innovator small molecule APIs for oncology indications. For more information, visit www.ashstevens.com.

###